Navigation Links
First-of-Its-Kind Study Shows Botox (Botulinum Toxin Type A),Significantly Improves Idiopathic Detrusor Overactivity (IDO) in,Patients With Symptoms of Overactive Bladder

Treatment Benefits Were Maintained for at Least 24 Weeks, According to Report Published in The Journal of Urology

LONDON, May 15, 2007 /PRNewswire/ -- Researchers from Guy's Hospital and King's College London School of Medicine have announced the results from the first randomized, double-blind, placebo-controlled study evaluating botulinum toxin type A (BTX-A, BOTOX(R)) as a treatment for idiopathic detrusor overactivity (IDO) in patients with symptoms of overactive bladder (OAB). The trial results which are published in the June 2007 issue of The Journal of Urology show that BTX-A is safe and effective for this use and that the beneficial effects -- including improved quality of life -- persist for at least 24 weeks.

"The findings of this study are important because there is a need for new treatments for OAB patients who have unsatisfactory responses to therapies which are currently available and who do not want to consider invasive surgery," said Mr. Arun Sahai, who was a principal investigator of the study during his time as a research fellow at Guy's Hospital, London. "This study demonstrated that botulinum toxin type A may be a promising treatment option for patients with OAB symptoms."

OAB is characterized by feelings of urgency to urinate, with or without incontinence, and is usually accompanied by increased urination frequency and nocturia (excessive urination at night). A large proportion of OAB patients have what is referred to as idiopathic detrusor overactivity or IDO -- excessive activity of the muscles that contract the bladder, due to an unknown cause -- and are treated with drugs called anticholinergics (e.g., tolterodine). However, many OAB patients discontinue medication due to insufficient relief of symptoms or intolerable side effects that can include dry mouth, dry eyes, constipation and headache.

"This study showed that this treatment had real benefits for patients for
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:4/27/2015)... BOULDER, Colo. , April 27, 2015 ... will report financial results for the third ... conference call to discuss those results on ... Executive Officer will lead the call.Date:Monday, May ... Code: 5249676 Webcast, including Replay and Conference ...
(Date:4/27/2015)... Inc. (NYSE: CRY ), a leading medical device ... surgery, announced today that it has received a close-out ... ("FDA") verifying that the Company has successfully implemented corrective ... received from the FDA in January 2013. ... by the FDA at CryoLife,s manufacturing facility and headquarters ...
(Date:4/27/2015)... NEW YORK , April 27, 2015   ... management solutions, will showcase advances in monitored care that ... the upcoming ATA 2015 Conference, May 2-5 ... Center. AMC Health will share information about ... monitored care to help transform and personalize healthcare delivery ...
Breaking Medicine Technology:CryoLife Announces Resolution of FDA Warning Letter 2AMC Health to Showcase Advances in Monitored Care at ATA 2015 2AMC Health to Showcase Advances in Monitored Care at ATA 2015 3AMC Health to Showcase Advances in Monitored Care at ATA 2015 4
... DIEGO, Oct. 13 RESMED INC. (NYSE: RMD ... will release its results for the first quarter of fiscal ... ResMed,s results will be issued after 1:00 p.m. Pacific Time ... to review its results, market trends, and future outlook. ...
... Care Continuum Alliance honored Kaiser Permanente,s ALL/PHASE initiative ... on Health" at The Forum 10 conference ... low-cost and generic medications and clinical interventions to reduce ... communities, including those served by safety net organizations. ...
Cached Medicine Technology:ResMed Announces Conference Call and Webcast to Discuss First Quarter 2011 Results 2Kaiser Permanente's ALL/PHASE Initiative Wins 2010 Care Continuum Alliance Quality Impact Award for Greatest Impact on Health 2Kaiser Permanente's ALL/PHASE Initiative Wins 2010 Care Continuum Alliance Quality Impact Award for Greatest Impact on Health 3
(Date:4/27/2015)... VA (PRWEB) April 27, 2015 A new ... on Saturday, May 9. Science on Tap at the Science ... favorite local brews, but adds science hops for a bold, ... music, food trucks and serves up the science behind these ... Homebrewers, get a first-hand look at the ingredients that go ...
(Date:4/27/2015)... UC Davis investigators have settled ... an inherited disorder that historically affected Ashkenazi Jews ... other populations of Semitic descent, particularly families from ... experiments, the researchers uncovered the biochemical underpinnings of ... an incurable and progressively fatal neurological condition. The ...
(Date:4/27/2015)... 27, 2015 Diamond reflective technology has ... of damaging hot spots. , Gorilla Grow Tents stand ... their sturdy structure and strong material that is lined ... to effectively distribute lumens and eliminates hot spots. ... from grow lights and produces the highest yield. The ...
(Date:4/27/2015)... April 27, 2015 Thanks to a ... researchers from a half-dozen institutions, including American University, will ... basic and social and behavioral research aimed at ending ... residents are living with HIV or AIDS, according to ... percent of D.C.'s population over the age of 13 ...
(Date:4/27/2015)... Guided by the extensive work of its community ... collaboration with organizations around the world to identify proven ... essential actions for organizations committed to patient experience ... systems committed to providing the best in experience will:, ... with committed time and focused intent to shape and ...
Breaking Medicine News(10 mins):Health News:Science on Tap at the Science Museum of Virginia 2Health News:UC Davis Makes Breakthrough in Understanding Canavan Disease 2Health News:UC Davis Makes Breakthrough in Understanding Canavan Disease 3Health News:UC Davis Makes Breakthrough in Understanding Canavan Disease 4Health News:D.C. Center for AIDS Research Established with New Grant from NIH 2Health News:D.C. Center for AIDS Research Established with New Grant from NIH 3Health News:Guiding Principles for Patient Experience Excellence Identified by The Beryl Institute 2
... While scientists and physicians know what happens if you don,t ... have long been puzzled about what controls the actual need ... Medicine might have an answer, at least in fruit flies. ... gene that controls sleep. , "We spend -- or ...
... Klein, former SVP Corporate Officer of Gillette, brings 38 years ... experience in consumer products ... leading,strategy consulting group, announced today that Peter Klein has joined ... of experience in the global consumer products,industry and was most ...
... problems may leave a mark on the brain, by ... sleep and problems with attention. For one in six ... that often trigger more frequent urges to urinate, such ... , "We often tend to focus on just ...
... friends and neighbors remember Lisa Sandler Spaeth as an ... lot on the go, juggling her son,s baseball games ... organizing women,s activities at her local synagogue. Add ... - making custom hair accessories for children - which ...
... must pass legislation to give FDA needed regulatory ... The following is a,statement by Ron Davis, M.D., ... the U.S. House of Representatives must take a ... ,Family Smoking and,Tobacco Control Act, and giving the ...
... 29 The Los Angeles Jewish Home,s,prestigious new Annenberg ... its second session as one of the only U.S. ... The Annenberg School of Nursing offers a full-time program ... for licensure. The,intensive vocational nursing program engages students 40 ...
Cached Medicine News:Health News:Searching for shut eye: Penn study identifies possible sleep gene 2Health News:The Cambridge Group Names Peter Klein a Director 2Health News:Findings on bladder-brain link may point to better treatments for problems in sleep, attention 2Health News:Note to people with scarred and stiffened lungs: Monitor your sleep before severe fatigue sets in 2Health News:Note to people with scarred and stiffened lungs: Monitor your sleep before severe fatigue sets in 3Health News:Note to people with scarred and stiffened lungs: Monitor your sleep before severe fatigue sets in 4Health News:Los Angeles Jewish Home's New Annenberg School of Nursing Seeks Applicants for Second Session of Precedent-Setting U.S. Senior-Care Facility's School of Nursing 2Health News:Los Angeles Jewish Home's New Annenberg School of Nursing Seeks Applicants for Second Session of Precedent-Setting U.S. Senior-Care Facility's School of Nursing 3
The ring maintains the bag tension avoiding the development of posterior capsule pleats. It is also established to compensate the efforts induced during the bag retraction....
... Type 14, 14A and 14C have been approved. ... to accommodate the variations in the size of ... tension rings are designed to stabilize the capsule ... large panel of U.S. ophthalmologists. For implatations ...
... is a device designed for permanent implantation ... removal surgery. It provides secondary capsular bag ... The CTR is a uniplanar, 270-degree, semi-circle ... absorbing polymethylmethacrylate (PMMA) with one manipulation eyelet ...
Stainless steel cartilage scissors....
Medicine Products: